GenLumina is pleased to announce that the Netherlands Patent Office has officially granted our patent based on the application filed on 24 April 2023. This milestone reinforces the scientific foundation of GenLumina’s light-activated nanomedicine platform and strengthens our intellectual property position in precision oncology.

The granted patent protects the core mechanism through which our nano-scale therapeutic enters the nucleus of tumor cells and becomes selectively activated by spatially guided light, leading to targeted destruction of cancer cells while sparing healthy tissue.

This achievement marks a significant step in our long-term strategy to develop novel therapeutic options for patients with hard-to-treat cancers. We see it as a strong validation of the underlying science and an important asset as we advance toward clinical translation.

Parallel patent applications in the United States, China, and Japan have entered the national examination phase, and we expect further outcomes in the coming period.